tenecteplase
Trade name: tnkase
Recombinant proteinapproved
Approved
Jun 2, 2000
Tenecteplase, sold under the brand name Tnkase among others, is an enzyme used as a thrombolytic drug. — Wikipedia
Clinical trial activity
100 trials · 117 clinical orgs · 1 marketing orgs
Phase 1
6
Phase 2
68
Phase 3
59
Phase 4
15
Earliest trial started May 1, 2000 (NCT02181985)
Timeline
Indications
Approved for
Studied for
- Acute Disease · Phase 2/Phase 3
- Arterial Occlusive Diseases · Phase 4
- Brain Diseases · Phase 2/Phase 3
- Brain Ischemia · Phase 2
- Catheters · Phase 3
- Central Nervous System Diseases · Phase 2/Phase 3
- Cerebral Arteries · Phase 2
- Cerebral Hemorrhage · Phase 1
- Cerebral Infarction · Phase 2
- Cerebrovascular Disorders · Phase 3
- COVID-19 · Phase 4
- Heart Arrest · Phase 3
- Hemodialysis, Home · Phase 3
- Hemorrhage · Phase 1
- Hemorrhagic Stroke · Phase 1
- Intracranial Hemorrhages · Phase 1
- Intracranial Thrombosis · Phase 3
- Ischemic Stroke · Phase 4
- Kidney Calculi · Phase 1/Phase 2
- Myocardial Infarction · Phase 4
- Nervous System Diseases · Phase 2
- Pharmacokinetics · Phase 3
- Pleural Effusion · Phase 2/Phase 3
- Pulmonary Embolism · Phase 4
- Respiratory Distress Syndrome · Phase 1
- Respiratory Insufficiency · Phase 2
- Retinal Artery Occlusion · Phase 3
- Severe Acute Respiratory Syndrome · Phase 2
- ST Elevation Myocardial Infarction · Phase 4
- Stroke · Phase 4
- Tenecteplase · Phase 3
- Thrombectomy · Phase 2
- Thrombosis · Phase 3
- Transportation of Patients · Phase 3
- Urinary Calculi · Phase 1/Phase 2
- Vascular Diseases · Phase 2/Phase 3
- Venous Cutdown · Phase 4
Mechanism of action
- PlasminogenACTIVATOR
PLG activator
- Tissue-type plasminogen activatorEXOGENOUS PROTEIN
Tissue-type plasminogen activator exogenous protein
Approval history
- approvedJun 2, 2000
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaTenecteplase ↗
- NCATSWGD229O42W ↗
- ChEMBLCHEMBL2108791 ↗
Also known as
- metalyse
- metalyse
- metalyse
- oms201
- rhtnk-tpa
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tenecteplase
- tnkase
- tnkase
- tnk-tissue plasminogen activator
- tnk-tpa
- tnk-tpa
- tnk-tpa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07253181 | Phase 3 | Dec 30, 2025 | Capital Medical University |
| NCT07294209 | Phase 4 | Dec 26, 2025 | People's Liberation Army of China |
| NCT06994975 | Phase 3 | Nov 30, 2025 | Fudan University |
| NCT06904911 | Phase 2 | Nov 15, 2025 | Genentech, University of Pennsylvania |
| NCT07168278 | Phase 3 | Nov 1, 2025 | University of Science and Technology of China |
| NCT07203625 | Phase 4 | Nov 1, 2025 | Capital Medical University |
| NCT06987305 | Phase 3 | Oct 1, 2025 | Nanchang University, People's Liberation Army of China |
| NCT07201688 | Phase 3 | Sep 30, 2025 | Government of China |
| NCT07073469 | Phase 3 | Sep 1, 2025 | Zhejiang University |
| NCT07092709 | Phase 3 | Aug 1, 2025 | Sun Yat-Sen University |
| NCT07047014 | Phase 3 | Jul 30, 2025 | Capital Medical University, Zhejiang University |
| NCT06949228 | Phase 2/Phase 3 (Phase 3) | Jul 30, 2025 | ProMedica Health System |
| NCT06801054 | Phase 1 | Jul 1, 2025 | Genentech, Memorial Hermann Health System, University of Texas at Houston |
| NCT06954155 | Phase 3 | May 30, 2025 | Capital Medical University |
| NCT06696131 | Phase 1 | Jan 15, 2025 | Rutgers University |
| NCT06769256 | Phase 4 | Jan 1, 2025 | Henan Institute of Cardiovascular Epidemiology |
| NCT06658197 | Phase 3 | Dec 1, 2024 | Capital Medical University |
| NCT06668441 | Phase 1 | Nov 1, 2024 | Capital Medical University |
| NCT06571149 | Phase 4 | Oct 31, 2024 | University of Bern |
| NCT06320431 | Phase 3 | Sep 26, 2024 | University of Calgary, University of New South Wales |
Showing 20 of 100 trials
Page 1 / 5
Organizations
Research & Development (117)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 16 | 16 | 4 | 2018 |
| Genentech | For profit | 13 | 5 | 4 | 2003 |
| Boehringer Ingelheim | For profit | 12 | 8 | 2 | 2000 |
| People's Liberation Army of China | Government | 10 | 10 | 3 | 2019 |
| Fudan University | Academic/Hospital | 4 | 3 | 2 | 2018 |
| Guangzhou Recomgen Biotech Co., Ltd. | For profit | 4 | 1 | 3 | 2016 |
| University of Calgary | Academic/Hospital | 4 | 4 | 2 | 2012 |
| University of Melbourne | Academic/Hospital | 4 | 3 | 1 | 2020 |
| Cerebrovascular Disease Collaboration & Innovation Alliance of Liaoning | Academic/Hospital | 3 | 0 | 1 | 2023 |
| Government of China | Government | 3 | 1 | 2 | 2021 |
| University of Alberta | Academic/Hospital | 3 | 2 | 3 | 2003 |
| University of Science and Technology of China | Academic/Hospital | 3 | 3 | 1 | 2023 |
| Emory University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Government of Brazil | Government | 2 | 0 | 1 | 2022 |
| Government of Norway | Government | 2 | 0 | 1 | 2012 |
| Hospital Moinhos de Vento | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 0 | 2 | 2021 |
| IQVIA | For profit | 2 | 0 | 1 | 2006 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Jilin University | Academic/Hospital | 2 | 0 | 2 | 2018 |
117 organizations
Page 1 / 6